Literature DB >> 15761864

Intronic sequence variants of the CDKN2A gene in melanoma pedigrees.

Mark Harland1, Claire F Taylor, Sylvia Bass, Michael Churchman, Juliette A Randerson-Moor, Elizabeth A Holland, Graham J Mann, D Timothy Bishop, Julia A Newton Bishop.   

Abstract

Germ-line mutations of the tumor-suppressor gene CDKN2A predispose individuals to melanoma in families worldwide. However, coding mutations of CDKN2A have not been detected in a significant proportion of those affected. The identification of a disease-associated intronic mutation of CDKN2A in UK families, which has proved to be the most common CDKN2A mutation as yet identified in this population, has highlighted the possibility that additional causal mutations may lie within the intronic sequence of the gene. In this article, we describe the comprehensive screening of 109 English and 26 Australian melanoma pedigrees for intronic mutations of CDKN2A. In total, 24 sequence variants were identified across the two introns of the gene. We show evidence that two of the CDKN2A intronic variants (IVS1 + 1104 C > A and IVS1 - 1104 C > G) predispose to melanoma. IVS1 + 1104 was shown to result in the aberrant splicing of both p16(INK4a) and p14(ARF) mRNA. Overall, however, the proportion of English melanoma families with these variants is small. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15761864     DOI: 10.1002/gcc.20177

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  6 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

Review 2.  Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer.

Authors:  Junan Li; Ming Jye Poi; Ming-Daw Tsai
Journal:  Biochemistry       Date:  2011-06-06       Impact factor: 3.162

Review 3.  Malignant melanoma in the 21st century: the emerging molecular landscape.

Authors:  Aleksandar Sekulic; Paul Haluska; Arlo J Miller; Josep Genebriera De Lamo; Samuel Ejadi; Jose S Pulido; Diva R Salomao; Erik C Thorland; Richard G Vile; David L Swanson; Barbara A Pockaj; Susan D Laman; Mark R Pittelkow; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2008-07       Impact factor: 7.616

Review 4.  Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Int J Cancer       Date:  2016-02-08       Impact factor: 7.396

5.  A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL).

Authors:  Mark Harland; Alisa M Goldstein; Kairen Kukalizch; Claire Taylor; David Hogg; Susana Puig; Celia Badenas; Nelleke Gruis; Jeanet ter Huurne; Wilma Bergman; Nicholas K Hayward; Mitchell Stark; Hensin Tsao; Margaret A Tucker; Maria Teresa Landi; Giovanna Bianchi Scarra; Paola Ghiorzo; Peter A Kanetsky; David Elder; Graham J Mann; Elizabeth A Holland; D Timothy Bishop; Julia Newton Bishop
Journal:  Eur J Cancer       Date:  2008-04-03       Impact factor: 9.162

6.  A melanoma molecular disease model.

Authors:  Smruti J Vidwans; Keith T Flaherty; David E Fisher; Jay M Tenenbaum; Michael D Travers; Jeff Shrager
Journal:  PLoS One       Date:  2011-03-30       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.